HCV and HIV infection and co-infection: Injecting drug use and sexual behavior, AjUDE-Brasil I Project

Cadernos de Saude Publica

Volumn 22, Issue 4, 2006, Pages 839-848

  Zocratto, Keli Bahia Felicíssimo ^a   Caiaffa, Waleska Teixeira ^a   Proietti, Fernando Augusto ^a   Carneiro Proietti, Anna Bárbara ^b   Mingoti, Sueli Aparecida ^a   Coelho Ribeiro, Geraldo José ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO HEMOMINAS   (Brazil)

^c Hospital Unimed Belo Horizonte   (Brazil)

Author keywords

Hepatitis C Virus; HIV; Intravenous Drug Abuse; Sexual Behavior

Indexed keywords

EID: 33646252917     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2006000400022     Document Type: Article

References (34)

1. World Health Organization. Hepatitis C - global prevalence. Wkly Epidemiol Rec 1999; 49:425-7.
2. World Health Organization. Global distribution of hepatitis A, B and C. Wkly Epidemiol Rec 2002; 77:45-7.
3. Taylor A, Goldberg D, Hutchhinson S, Cameron S, Gore SM, McMenamin J, et al. Prevalence of hepatitis C virus infection among injection drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000; 40:176-83.
4. Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, et al. Opportunities for Prevention: hepatitis C prevalence and incidence in cohort of young injection drug users. Hepatology 2002; 36:737-42.
5. Caiaffa WT, Mingoti SA, Proietti FA, Carneiro-Proietti AB, Silva RC, Lopes AC, et al. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project. J Urban Health 2003; 80:106-14.
6. Crofts N, Thompson S, Kaldor J. Epidemiology of hepatitis C virus. Canberra: Communicable Diseases Network, Australia and New Zealand; 1999.
7. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C co-infection within the CAESAR study. HIV Med 2004; 5:174-9.
8. Garfein RS, Doherty MC, Monterroso E. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 Suppl 1:11-9.
9. Fletcher S. Sexual transmission of hepatitis C and early intervention. J Assoc Nurses AIDS Care 2003; 14 Suppl 5:87-94.
10. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395-402.
11. Joint United Nations Programme on HIV/AIDS. UNAIDS 2004 report on the global AIDS epidemic. http://www.unaids.org/bangkok2004/report_ pdf.html (accessed on 03/Jun/2005).
12. Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, Doneda D, Gandolfi D, et al. The dynamics of the human immunodeficiency virus epidemic in the south of Brazil: increasing role of injection drug users. Clin Infect Dis 2003; 37 Suppl 5:376-81.
13. Bruno R, Sacchi P, Puoti M, Soriano V, Filice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002; 97:1598-606.
14. Monteiro MR, Nascimento MM. Hepatite C: prevalência e fatores de risco entre portadores do HIV/SIDA em Belém, Pará, na Amazônia Brasileira. Rev Soc Bras Med Trop 2004; 37 Suppl 2:40-6.
15. Segurado AC, Braga P, Etzel A, Cardoso MR. Hepatitis C virus co-infection in a cohort of HIV-infected individuals from Santos, Brazil: seroprevalence and associated factors. AIDS Patient Care STDS 2004; 18:135-43.
16. Camino N, Sheldon J, Soriano V. Update on hepatitis C treatment in HIV co-infected patients. Minerva Gastroenterol Dietol 2004; 50:67-77.
17. Braitstein P, Yip B, Montessori V, Moore D, Montaner JS, Hogg RS. Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. CMAJ 2005; 173:160-4.
18. Daniel S. Chronic hepatitis C treatment patterns in African-American patients: an update. Am J Gastroenterol 2005; 100:716-22.
19. Di Martino V, Boyer N, Renard P, Degos F, Marinot-Peignoux M, Matheron S, et al. The influence of human immunodeficiency coinfection on chronic hepatitis in injection drug users: a study. Hepatology 2001; 34:1193-9.
20. Caiaffa WT. Projeto Ajude-Brasil. Avaliação epidemiológica dos usuários de drogas injetáveis dos projetos de redução de danos apoiados pela CN-DST/AIDS. Brasília: Ministério da Saúde; 2001.
21. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 2000.
22. Hagan H, Thiede H, Weiss NS, Hopikins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-6.
23. Hahn JA, Page-Shafer K, Lum PJ, Bourgouis P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infec Dis 2002; 186:1558-64.
24. Garten RJ, Lai S, Zhang J, Chen J, Vlahov D, Yu SF. Rapid Transmission of hepatitis C virus among injecting heroin users in Southern China. Int J Epidemiol 2004; 33:182-8.
25. Burattini MN, Massad E, Rozman M, Azevedo RS, Carvalho HB. Correlation between HIV and HCV in Brazilian prisoners: evidence from parenteral transmission inside prison. Rev Saúde Pública 2000; 34:431-6.
26. Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health 2003; 80 (4 Suppl 3):7-14.
27. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-9.
28. Hacker MA, Friedman SR, Telles PR, Teixeira SL, Bongertz V, Morgado M, et al. The role of "long-term" and "new" injectors in a declining HIV/AIDS epidemic in Rio de Janeiro, Brazil: a report from the WHO drug injection study phase II. Subst Use Misuse 2005; 40:1-31.
29. Rey D, Carrieri MP, Spire B, Loubiere S, Dellamonica P, Gallais H, et al. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J Urban Health 2004; 81:48-57.
30. Friedman SR, Aral S. Social networks, risk-potential networks, health, and disease. J Urban Health 2001; 78:411-8.
31. Deslandes SF, Mendonça EA, Caiaffa WT, Doneda D. As concepções de risco e de prevenção segundo ótica dos usuários de droga injetáveis. Cad Saúde Pública 2002; 18:141-51.
32. Ferreira AD, Caiaffa WT, Bastos FI, Mingoti SA; Projeto AjUDE-Brasil II. Profile of male Brazilian injecting drug users who have sex with men. Cad Saúde Pública 2006; 22:849-60.
33. Simões AM, Bastos FI. Audio computer-assisted interview: a new technology in the assessment of sexually transmitted diseases, HIV, and drug use. Cad Saúde Pública 2004; 20:1169-81.
34. Centers of Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Morb Mortal Wkly Rep 2003; 52:1-15.